RARB and cancer: Moreover, we found that treatment with the p38-specific agonist Dehydrocorydaline restored the proliferation, whereas suppressed the apoptosis of cancer cells induced by DLEU2 knockdown, which confirmed that the DLEU2/RARB axis regulates CRC tumorigenesis by manipulating the MAPK signaling pathway.